Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding
knowledge of ovarian cancer immunology has allowed the development of therapies that …

While therapeutic vaccines for ovarian cancer represent only a small fraction of active
clinical trials, growing interest in this area and the accumulated data supporting the use of …

Ovarian cancer vaccines are one of the new treatment strategies under investigation in
epithelial ovarian cancer. This article discusses the results of different immunization …

Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death.
Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and …

Ovarian cancer is responsible for the majority of gynecologic cancer deaths and despite the
highest standard of multimodality therapy with surgery and cytotoxic chemotherapy, long …

After decades of extensive research, epithelial ovarian cancer still remains a lethal disease.
Multiple new studies have reported that the immune system plays a critical role in the growth …

Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies and
the fifth most frequent cause of cancer death in women [1]. Malignant ovarian tumors are the …

Simple Summary The overall survival of ovarian cancer (OC) remains poor for most patients.
Despite incorporation of novel therapeutic agents such as bevacizumab and PARP …

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based
vaccination could integrate the current standard of care for the treatment of a large variety of …